Welcome to our dedicated page for Akoya BioSciences news (Ticker: $AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akoya BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akoya BioSciences's position in the market.
Akoya Biosciences, Inc. has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the increasing demand for its spatial biology solutions. The facility aims to drive operational efficiencies, enhance customer service, and expand the company's portfolio. The 32,000 square foot facility includes R&D, manufacturing, quality control, warehouse space, and distribution, emphasizing cross-functional collaboration and faster product development.
Akoya Biosciences and Shanghai KR Pharmtech have announced that KR-HT5, developed using Akoya's PhenoImager HT technology, has received premarket approval from China's NMPA. This approval will support next generation pathology clinical workflows in China, providing clinicians with a high-throughput platform for multiplex biomarker analysis. Shanghai KR Pharmtech will offer KR-HT5 as part of its Next Generation Pathology solutions.
